Abstract
Despite advances in surgery, radiation, and medical therapy over the past decade and the widespread adoption of PSA screening, prostate cancer continues to be the second leading cause of cancer death in men in the United States. Invasive cancer is the end result of carcinogenesis, a chronic process occurring over many years driven by genetic and epigenetic alterations. The protracted nature of this transformation to the malignant phenotype provides an opportunity to intervene pharmacologically to prevent, reverse, or delay carcinogenesis, i.e. chemoprevention. Herein, we describe the unique features of cancer prevention, as opposed to cancer treatment, agent development clinical trials, and provide a summary of the ongoing research in this field being supported by the National Cancer Institute.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Algotar AM, Stratton MS, Ahmann FR et al (2013) Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73(3):328–335
Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–202
Bostwick DG, Qian J (2001) Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 58:91–93
Carducci MA WJ, Heath E, et al (2007) A randomized, placebo-controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized adenocarcinoma of the prostate: evaluation of drug-specific biomarker modulation. Suppl J Clin Oncol ASCO Annu Meet Proc 25:235s
Carter HB, Kettermann A, Warlick C et al (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359–2364 (Discussion 64–65)
Chan JM, Weinberg V, Magbanua MJ et al (2011) Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control 22:141–150
Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19
De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992
Huang X, Chen S, Xu L et al (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65:3470–3478
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428
Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170
Klein EA, Thompson IM Jr, Tangen CM et al (2011) Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 306:1549–1556
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131
Kronz JD, Allan CH, Shaikh AA, Epstein JI (2001) Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 25:1079–1085
Kumar NB, Krischer JP, Allen K et al (2007) A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 59:163–168
Kumar N (2011) Personal communication
Lippman SM, Hong WK (2002) Cancer prevention science and practice. Cancer Res 62:5119–5125
Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 301:39–51
Marshall JR, Tangen CM, Sakr WA et al (2011) Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 4:1761–1769
Nguyen MM, Ahmann FR, Nagle RB et al (2012) Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 5:290–298
Ozten-Kandas N, Bosland MC (2011) Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants—in vivo evidence. J Carcinog 10:27
Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R (2004) Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention Portfolio. J Urol 171:S68–74. Discussion S5
Renan MJ (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139–146
Sabichi AL, Lee JJ, Taylor RJ et al (2006) Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a southwest oncology group study. Clin Cancer Res 12:2178–2184
Schulman CC, Zlotta AR, Denis L, Schroder FH, Sakr WA (2000) Prevention of prostate cancer. Scand J Urol Nephrol Suppl 205:50–61
Simoneau AR, Gerner EW, Nagle R et al (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomark Prev 17:292–299
Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes HL (2012) Active surveillance for prostate cancer: past, present and future. Curr Opin Oncol 24:243–250
Sporn MB, Suh N (2000) Chemoprevention of cancer. Carcinogenesis 21:525–530
Sporn MB, Suh N (2002) Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2:537–543
Stratton MS, Algotar AM, Ranger-Moore J et al (2010) Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 3:1035–1043
Thompson IM, Ankerst DP, Chi C et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 98:529–534
Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224
Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC (2012) A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology 80(484):e17–e22
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Parnes, H.L., House, M.G., Tangrea, J.A. (2014). Prostate Cancer Prevention: Agent Development Strategies. In: Cuzick, J., Thorat, M. (eds) Prostate Cancer Prevention. Recent Results in Cancer Research, vol 202. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45195-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-45195-9_15
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45194-2
Online ISBN: 978-3-642-45195-9
eBook Packages: MedicineMedicine (R0)